Point of Care Nano-Tech Files Q3 10-Q
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
**PCNT files Q3 10-Q. Bio-tech company updates financials.**
AI Summary
Point of Care Nano-Technology, Inc. filed a 10-Q for the period ending April 30, 2024. The company, formerly known as Alternative Energy & Environmental Solutions, Inc., is in the biological products sector. Their fiscal year ends on July 31st.
Why It Matters
This filing provides an update on the financial health and operational status of Point of Care Nano-Technology, Inc. for investors and stakeholders.
Risk Assessment
Risk Level: low — This is a routine quarterly filing with no immediate red flags or significant new risks disclosed.
Key Numbers
- 0731 — Fiscal Year End (Indicates when the company's financial year concludes.)
- 0430 — Reporting Period End (Marks the end date for the financial data presented in this 10-Q.)
Key Players & Entities
- Point of Care Nano-Technology, Inc. (company) — Filer of the 10-Q
- Alternative Energy & Environmental Solutions, Inc. (company) — Former name of the filer
- 0731 (date) — Fiscal year end
- 0430 (date) — End of reporting period
FAQ
What is the primary business of Point of Care Nano-Technology, Inc.?
Point of Care Nano-Technology, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
When is Point of Care Nano-Technology, Inc.'s fiscal year end?
The company's fiscal year ends on July 31st (0731).
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending April 30, 2024 (0430).
Has the company's name changed previously?
Yes, the company was formerly known as Alternative Energy & Environmental Solutions, Inc., with a name change date of October 25, 2010 (20101025).
What is the company's business address?
The business address is 531 US HWY 22 EAST, SUITE 232, WHITEHOUSE STATION, NJ 08889.
Filing Stats: 4,667 words · 19 min read · ~16 pages · Grade level 14.8 · Accepted 2024-12-23 13:17:49
Key Financial Figures
- $20,000 — pleted a financing with an investor for $20,000 in exchange for Units consisting of (i)
- $0.0001 — i) one share of common stock, par value $0.0001 per share for $0.10 per share, (ii) one
- $0.10 — stock, par value $0.0001 per share for $0.10 per share, (ii) one LOI option to purch
- $0.20 — purchase one share of common stock for $0.20 per share upon the Company signing a le
- $0.30 — purchase one share of common stock for $0.30 per share upon the Company signing an a
Filing Documents
- pcnt-10q.htm (10-Q) — 555KB
- pcnt-ex31.htm (EX-31.1) — 15KB
- pcnt-ex32.htm (EX-32.1) — 6KB
- 0001199835-24-000559.txt ( ) — 1890KB
- pcnt-20240430_pre.xml (EX-101.PRE) — 83KB
- pcnt-20240430_lab.xml (EX-101.LAB) — 107KB
- pcnt-20240430_def.xml (EX-101.DEF) — 20KB
- pcnt-20240430_cal.xml (EX-101.CAL) — 19KB
- pcnt-20240430.xsd (EX-101.SCH) — 16KB
- pcnt-10q_htm.xml (XML) — 213KB
—FINANCIAL
PART I—FINANCIAL INFORMATION Item 1. Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets as of April 30, 2024 (unaudited) and July 31, 2023 3 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended April 30, 2024 (unaudited) and the Three and Nine Months Ended April 30, 2023 (unaudited) 4 Condensed Consolidated Statements of Changes in Statements of Equity for the Three and Nine Months Ended April 30, 2024 (unaudited) and the Three and Nine Months Ended April 30, 2023 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended April 30, 2024 (unaudited) and the Three and Nine Months Ended April 30, 2023 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7 Item 2.
Managements Discussion and Analysis of Financial Condition and Results of Operations
Managements Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 14 Item 4.
Controls and Procedures
Controls and Procedures 14
—OTHER INFORMATION
PART II—OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 15 Item 1A.
Risk Factors
Risk Factors 15 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15 Item 3. Defaults Upon Senior Securities 15 Item 4. Mine Safety Disclosures 15 Item 5. Other Information 15 Item 6. Exhibits 16
SIGNATURES
SIGNATURES 17 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for Point of Care Nano-Technology, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as may, will, expect, intend, anticipate, believe, estimate and continue or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors in the Companys 10K/A filed with the Securities and Exchange Commission (SEC) on October 31, 2024. 2 Table of Contents ITEM 1. FINANCIAL STATEMENTS POINT OF CARE NANO-TECHNOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of April 30, 2024 (Unaudited) and July 31, 2023 April 30, 2024 July 31, 2023 ASSETS Current Assets Cash $ 12 $ 498 Prepaid Expenses 960 5,280 Current Assets 972 5,778 Intangible Asset - License (Note 7) 110,237 118,865 Total Assets $ 111,209 $ 124,643 LIABILITIES AND STOCKHOLDERS DEFICIT Current Liabilities Accounts Payable and Accrued Expenses $ 145,951 $ 141,414 Total Liabilities 145,951 141,414 Stockholders Deficit Preferred Stock, par value $ .0001 , (Note 5) 10,000,000 shares authorized; 1,000 shares issued and outstanding 1 1 Common Stock, par value $ .000